The Latest From CureMatch
CureMatch, Inc., a healthcare technology company using precision medicine support for oncology, is proud to announce a collaboration with the Mark Cuban Cost Plus Drug Company, PBC (Cost Plus Drugs). Together, the companies aim to make cancer treatments more affordable and accessible to all Americans. Through the relationship announced today, patients with a CureMatch report […]
CureMatch, Inc., a healthcare technology company leveraging Knowledge Representation & Reasoning (KRR) AI for precision medicine support for oncology, today announced that the organization has become a proud member of CancerX. CancerX is a public-private partnership launched by The White House, which aims to be a national accelerator boosting innovation in the fight against cancer […]
CureMatch will leverage mProbe’s targeted proteomics platform to assess individual proteins within patients’ tumor tissues. CureMatch, Inc., a healthcare technology company that leverages artificial intelligence (AI) to power precision medicine support for oncology, is proud to announce a collaboration with mProbe Inc., a premier CLIA-certified targeted proteomics company. mProbe utilizes a proprietary technology platform integrating […]
Oncologists will be able to submit claims to payers using a Category III CPT code, paving the way for wider adoption of precision treatment options. CureMatch, Inc., a leader in precision medicine support for oncology, is pleased to announce that the American Medical Association (AMA) has issued the new Current Procedural Terminology (CPT®) Category III […]
